Compared to patients with decreased TGF-β1 after CRT, patients with persistently elevated TGF-β1 after CRT experienced an earlier tumor progression (mean PFS survival of 7.8 months vs 24.8 months, p = 0.013, Fig 3c), and overall survival difference was not statistically significance (mean overall survival of 22.2 months vs 31.6 months, p = 0.200, Fig 3d). This evidence concerns the gene TGFB1 and neoplasm.